Saturday - May 18, 2024
Pfizer: XTANDI Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients With NmCRPC
February 12, 2020
NEW YORK, Feb. 12 -- Pfizer, a pharmaceutical company, issued the following news release:

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) announced results of the final overall survival (OS) analysis from the Phase 3 PROSPER trial, which evaluated XTANDI(R) (enzalutamide) plus androgen deprivation therapy (ADT) versus placebo plus ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC). . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products